Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Blood-Brain Barrier (BBB) Regulation and Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for GPR124/ADGRA2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | GPR124 ECD-Fc Fusion Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View GPR124 Products |
| Gene Delivery | GPR124 Lentivirus Premade Particles Full-length ORF for stable cell line generation. |
View GPR124 Products |
| Benchmark Ab | Anti-GPR124 Recombinant Antibody Recombinant positive control for assay validation. |
View GPR124 Products |
| Validator | GPR124 siRNA Set For knockdown verification. |
View GPR124 Products |
| Related Target A | RECK Essential membrane co-receptor required for functional GPR124-mediated Wnt/beta-catenin signaling. |
View RECK Products |
| Related Target B | Wnt7a Specific ligand that synergizes with RECK to activate the GPR124 signaling cascade. |
View Wnt7a Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Conformational Integrity of GPCR | Lentivirus premade particles for robust cell-surface expression in functional assays |
| Glycosylation-dependent Ligand Binding | HEK293-expressed ECD-Fc proteins preserving native post-translational modifications |
| Lack of Controls | Recombinant positive control antibodies sequence-verified |
| Target Specificity Verification | Validated siRNA set for target gene knockdown |
Live GPR124/ADGRA2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for GPR124/ADGRA2 therapeutics is intensifying, with major players shifting focus from traditional mAbs to blood-brain barrier (BBB) modulating biologicals and tumor-targeted antibody-drug conjugates (ADCs). As first-generation therapies reach the clinic, the next wave of R&D is targeting receptor-mediated transcytosis and Wnt-pathway restoration in neurovascular diseases.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (Agonistic) | Academic Consortia, CNS Biotechs | Ischemic Stroke, BBB Breakdown | Functional cell-based assays (Need Lentivirus for Stable Cell Line) |
| Targeted Delivery / Vector | Brain-penetrating Therapeutics Developers | CNS Drug Delivery, Glioblastoma | Binding affinity to native conformation (Need Lentivirus-driven target expression) |
| Antigenic Inhibitors | Oncology-focused Biopharma | Tumor Angiogenesis, Solid Tumors | Epitope mapping & ligand blocking (Need High-Purity ECD-Fc Proteins) |